Skip to main content

Advertisement

Table 7 Post-treatment changes of lymphocytes and immunoglobulins

From: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

  Baseline values and post-treatment percent change from baseline (mean ± SD)
  Baseline 6 weeks 10 weeks 18 weeks 32 weeks
Lymphocytes N = 14 N = 6 N = 8 N = 9 N = 11
   B cells 123 ± 160 cells/μl -35% ± 23% -41% ± 41% -34% ± 23% -44% ± 21%
   T cells 744 ± 554 cells/μl +16% ± 80% +28% ± 78% +47% ± 109% +17% ± 69%
Immunoglobulins   N = 12 N = 14 N = 10 N = 11
   IgG 1,252 ± 355 mg/dl +3% ± 8% +5% ± 13% +5% ± 9% 1% ± 13%
   IgA 226 ± 94 mg/dl +3% ± 11% +8 ± 13% +5% ± 12% +10% ± 20%
   IgM 117 ± 73 mg/dl -12% ± 18% -1% ± 23% -6% ± 19% -9% ± 9%
  1. SD, standard deviation.